Please assess the completion status of the following clinical trial:

Trial Title: Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed metastatic malignant melanoma that is considered unresectable~  * Stage III or IV ocular, mucosal, or cutaneous melanoma~* Measurable disease~* No CNS disease (phase I only)~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 70-100%~Life expectancy:~* Not specified~Hematopoietic:~* Absolute granulocyte count at least 1,500/mm\^3~* Platelet count at least 150,000/mm\^3~Hepatic:~* Bilirubin no greater than 1.5 times upper limit of normal (ULN)~* SGOT/SGPT no greater than 3 times ULN~* Alkaline phosphatase no greater than 3 times ULN~Renal:~* Creatinine no greater than 1.5 times ULN~Cardiovascular:~* No history of active angina~* No myocardial infarction within past 6 months~* No history of significant ventricular arrhythmia requiring medication with antiarrhythmics~Other:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective barrier contraception during and for 4 weeks before and after study~* No frequent vomiting or medical condition that could interfere with oral medication intake (e.g., partial bowel obstruction)~* No preexisting neurotoxicity grade 2 or greater~* No serious concurrent infections treated with antibiotics~* No nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the complications of this study~* No psychiatric disorders that would preclude study compliance~* No other medical condition or reason that would preclude study~* No other malignancy within the past 2 years except:~  * Nonmelanoma skin cancer~ * Carcinoma in situ of the cervix~ * History of T1a or b prostate cancer detected incidentally at TURP and comprising less than 5% of resected tissue with PSA normal since TURP~* No AIDS related illness~* HIV negative~PRIOR CONCURRENT THERAPY:~* Recovered from prior therapy~Biologic therapy:~* At least 4 weeks since prior biologic therapy~* At least 4 weeks since prior immunotherapy~* No concurrent immunotherapy~Chemotherapy:~* No prior systemic chemotherapy for metastatic melanoma~* No other concurrent chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* At least 4 weeks since prior radiotherapy, interstitial brachytherapy, or radiosurgery~* At least 3 weeks since prior radiotherapy to the brain if brain metastases from melanoma~* Prior radiotherapy to only indicator lesion allowed provided recent evidence of disease progression at that site~* No concurrent radiotherapy~Surgery:~* At least 2 weeks since prior surgery requiring general anesthesia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).